

Leishmaniasis (Kala-Azar) Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre- clinical and Clinical Drugs

<https://marketpublishers.com/r/L29E9579F3B3EN.html>

Date: October 2019

Pages: 100

Price: US\$ 1,699.00 (Single User License)

ID: L29E9579F3B3EN

Abstracts

Leishmaniasis (Kala-Azar) Drug pipeline report- 2020 is an annual R&D review of Leishmaniasis (Kala-Azar) pipeline candidates. The report presents the current status of all major Leishmaniasis (Kala-Azar) therapeutic compounds. Detailed insights into Leishmaniasis (Kala-Azar) pipeline development, current status, companies, drug profiles and Leishmaniasis (Kala-Azar) preclinical and clinical trials are included.

2020 Leishmaniasis (Kala-Azar) Pipeline Market Insights

Leishmaniasis (Kala-Azar) disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Leishmaniasis (Kala-Azar) therapies, pipeline by phase and others are included.

Leishmaniasis (Kala-Azar) pipeline Drug profiles-

Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Leishmaniasis (Kala-Azar) Therapeutic Drug candidates

Both active and inactive Leishmaniasis (Kala-Azar) pipeline drug candidates are included in the report

Leishmaniasis (Kala-Azar) Clinical Trials and preclinical Studies

Leishmaniasis (Kala-Azar) In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other

details are provided.

Leishmaniasis (Kala-Azar) pipeline market developments
Leishmaniasis (Kala-Azar) Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Leishmaniasis (Kala-Azar) pipeline companies in active development
The report analyzes Leishmaniasis (Kala-Azar) pipeline of the below companies-

Acea Biotech Inc, Anacor Pharmaceuticals , BioLingus AG, Cerenis Therapeutics Holding SA, Daiichi Sankyo Co Ltd, DetectoGen Inc, DNDi, Eurofins Advinus Ltd, Farmabrazilis, Fondation MEDINA, GlaxoSmithKline Plc, iCo Therapeutics Inc., Immune Modulation Inc, ManRos Therapeutics, Matinas BioPharma, Mindmed, Mologen AG, Novartis AG, Pfizer, Rakta Therapeutics Inc, Savant HWP Inc, Sequella Inc

Report Coverage

What to look out for in 2020

Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

Pipeline Snapshot

Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

Companies

22 Companies investing in Leishmaniasis (Kala-Azar) pipeline from discovery stage to pre-registration phase are included

Drug profiles

Over 10 details of each Leishmaniasis (Kala-Azar) pipeline candidate are included

Company Profiles

Business overview and contact details of all companies operating in the industry are provided

Market Developments

News, Developments and other recent industry developments are included

Contents

1. LEISHMANIASIS (KALA-AZAR) PIPELINE MARKET INSIGHTS, 2020

- 1.1 Leishmaniasis (Kala-Azar) Disease Overview
- 1.2 Leishmaniasis (Kala-Azar) Drug Pipeline Snapshot, 2020
 - 1.2.1 Leishmaniasis (Kala-Azar) Pipeline Drugs by Phase
 - 1.2.2 Leishmaniasis (Kala-Azar) Pipeline Drugs by Company
 - 1.2.3 Leishmaniasis (Kala-Azar) Pipeline Drugs by Mechanism of Action
 - 1.2.4 Leishmaniasis (Kala-Azar) Pipeline Drugs by Route of Administration

2. LEISHMANIASIS (KALA-AZAR) COMPANY WISE PIPELINE DETAILS

Acea Biotech Inc Leishmaniasis (Kala-Azar) Pipeline Drugs

- Company Profile

- Drug Candidate Details

Anacor Pharmaceuticals Leishmaniasis (Kala-Azar) Pipeline Drugs

- Company Profile

- Drug Candidate Details

BioLingus AG Leishmaniasis (Kala-Azar) Pipeline Drugs

- Company Profile

- Drug Candidate Details

Cerenis Therapeutics Holding SA Leishmaniasis (Kala-Azar) Pipeline Drugs

- Company Profile

- Drug Candidate Details

Daiichi Sankyo Co Ltd Leishmaniasis (Kala-Azar) Pipeline Drugs

- Company Profile

- Drug Candidate Details

DetectoGen Inc Leishmaniasis (Kala-Azar) Pipeline Drugs

- Company Profile

- Drug Candidate Details

DNDi Leishmaniasis (Kala-Azar) Pipeline Drugs

- Company Profile

- Drug Candidate Details

Eurofins Advinus Ltd Leishmaniasis (Kala-Azar) Pipeline Drugs

- Company Profile

- Drug Candidate Details

Farmabrazilis Leishmaniasis (Kala-Azar) Pipeline Drugs

- Company Profile

Drug Candidate Details
Fondation MEDINA Leishmaniasis (Kala-Azar) Pipeline Drugs
Company Profile
Drug Candidate Details
GlaxoSmithKline Plc Leishmaniasis (Kala-Azar) Pipeline Drugs
Company Profile
Drug Candidate Details
iCo Therapeutics Inc. Leishmaniasis (Kala-Azar) Pipeline Drugs
Company Profile
Drug Candidate Details
Immune Modulation Inc Leishmaniasis (Kala-Azar) Pipeline Drugs
Company Profile
Drug Candidate Details
ManRos Therapeutics Leishmaniasis (Kala-Azar) Pipeline Drugs
Company Profile
Drug Candidate Details
Matinas BioPharma Leishmaniasis (Kala-Azar) Pipeline Drugs
Company Profile
Drug Candidate Details
Mindmed Leishmaniasis (Kala-Azar) Pipeline Drugs
Company Profile
Drug Candidate Details
Mologen AG Leishmaniasis (Kala-Azar) Pipeline Drugs
Company Profile
Drug Candidate Details
Novartis AG Leishmaniasis (Kala-Azar) Pipeline Drugs
Company Profile
Drug Candidate Details
Pfizer Leishmaniasis (Kala-Azar) Pipeline Drugs
Company Profile
Drug Candidate Details
Rakta Therapeutics Inc Leishmaniasis (Kala-Azar) Pipeline Drugs
Company Profile
Drug Candidate Details
Savant HWP Inc Leishmaniasis (Kala-Azar) Pipeline Drugs
Company Profile
Drug Candidate Details
Sequella Inc Leishmaniasis (Kala-Azar) Pipeline Drugs
Company Profile

Drug Candidate Details

3. LEISHMANIASIS (KALA-AZAR) DRUG PIPELINE PROFILES

3.1 Discovery and Preclinical Drug Profiles

3.2 Phase 1 Drug Profiles

3.3 Phase 2 Drug Profiles

3.4 Phase 3 Drug Profiles

4. LEISHMANIASIS (KALA-AZAR) PIPELINE NEWS AND DEVELOPMENTS

5. APPENDIX

5.1 Primary and Secondary Research Methodology

5.2 Publisher Expertize

5.3 Contacts

I would like to order

Product name: Leishmaniasis (Kala-Azar) Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

Product link: <https://marketpublishers.com/r/L29E9579F3B3EN.html>

Price: US\$ 1,699.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/L29E9579F3B3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970